Ergoteles LLC Fibrogen Inc Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$15.95 - $25.18 $337,326 - $532,531	-21,149 Reduced 34.3%	40,509 $755,000
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $528,159 - $705,671	-39,801 Reduced 39.23%	61,658 $987,000
Q3 2022 Nov 14, 2022	BUY	$11.4 - $14.6 $406,432 - $520,519	35,652 Added 54.18%	101,459 $1.32 Million
Q2 2022 Aug 12, 2022	BUY	$7.94 - $12.96 $59,248 - $96,707	7,462 Added 12.79%	65,807 $695,000
Q1 2022 May 13, 2022	BUY	$12.02 - $16.79 $100,463 - $140,330	8,358 Added 16.72%	58,345 $701,000
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $496,370 - $769,299	49,987 New	49,987 $705,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.